KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $155.1 million.

  • Recursion Pharmaceuticals' Total Current Liabilities rose 42.44% to $155.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.1 million, marking a year-over-year increase of 42.44%. This contributed to the annual value of $187.5 million for FY2024, which is 101.21% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Total Current Liabilities is $155.1 million, which was down 5.44% from $164.0 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Total Current Liabilities peaked at $187.5 million during Q4 2024, and registered a low of $26.9 million during Q1 2021.
  • In the last 3 years, Recursion Pharmaceuticals' Total Current Liabilities had a median value of $108.9 million in 2024 and averaged $119.2 million.
  • In the last 5 years, Recursion Pharmaceuticals' Total Current Liabilities spiked by 227.19% in 2022 and then fell by 24.46% in 2024.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Total Current Liabilities stood at $46.7 million in 2021, then spiked by 114.89% to $100.3 million in 2022, then dropped by 7.08% to $93.2 million in 2023, then spiked by 101.21% to $187.5 million in 2024, then spiked by 42.44% to $155.1 million in 2025.
  • Its last three reported values are $155.1 million in Q3 2025, $164.0 million for Q2 2025, and $142.0 million during Q1 2025.